ClinicalTrials.gov
public full text
Public Domain
Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma
This is a prospective pilot study that will document the clinical experience of 30 patients with unresectable hepatocellular carcinoma undergoing liver-directed therapy with Yttrium-90 glass microspheres (TheraSphere®).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy#862541
- Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases#272346
- Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma#913089
- Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer#904823
- Hepatocellular carcinoma metastasis to salivary glands: a systematic review of diagnostic challenges and survival outcomes.#360760
Record · ID 1407408
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive